From Wikipedia, the free encyclopedia
Jump to: navigation, search
Clinical data
AHFS/ International Drug Names
Routes of
s.c. injection only, premedication with H1 and H2 antihistamines and beta-receptor agonists for bronchodilation
ATC code
Pharmacokinetic data
Biological half-life 2.5 h
Excretion renal: 90%
CAS Number
  • none
 NYesY (what is this?)  (verify)

Ancestim is a recombinant methionyl human stem cell factor, branded by Amgen as StemGen. It was developed by Amgen and sold to Biovitrium, now Swedish Orphan Biovitrum, in December, 2008.[1]

It is a 166 amino acid protein produced by E. coli bacteria into which a gene has been inserted for soluble human stem cell factor.[2] It has a monomeric molecular weight of approximately 18,500 daltons and normally exists as a noncovalently associated dimer. The protein has an amino acid sequence that is identical to the natural sequence predicted from human DNA sequence analysis, except for the addition of an N-terminal methionine retained after expression in E. coli. Because Ancestim is produced in E. coli, it is nonglycosylated. Ancestim is supplied as a sterile, white, preservative-free, lyophilised powder for reconstitution and administration as a subcutaneous (SC) injection and is indicated for use in combination with filgrastim for mobilizing peripheral hematopoietic stem cells for later transplanation in certain cancer patients.[3]


  1. ^ Amgen press office. Biovitrum Closes Product Acquisition Deal with Amgen Archived July 3, 2012, at the Wayback Machine.
  2. ^ da Silva MG, Pimentel P, Carvalhais A, et al. (2004). "Ancestim (recombinant human stem cell factor, SCF) in association with filgrastim does not enhance chemotherapy and/or growth factor-induced peripheral blood progenitor cell (PBPC) mobilization in patients with a prior insufficient PBPC collection". Bone Marrow Transplant. 34 (8): 683–91. PMID 15322567. doi:10.1038/sj.bmt.1704602. 
  3. ^ Sobi's StemGen page]